Topical Indomethacin Therapy Before Argon Laser Trabeculoplasty

Pappas, Harry R.; Berry, David P.; Partamian, Leon G.; Hertzmark, Ellen; Epstein, David L.

doi:10.1016/s0002-9394(14)77961-9

Cited by 30 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the influence of prostaglandin use must be prospectively evaluated with potential implications for the use of topical non-steroidal anti-inflammatory drugs post-treatment. 66,67 Our study demonstrates lowest failure rates (50%) for those patients on no medications and highest failure rates (73%) for those taking 4 medications; a majority (92%) of our patients was on topical therapy at the time of SLT treatment. Perhaps SLT may function better as primary therapy rather than secondary or tertiary therapy.…”

Section: Discussionmentioning

confidence: 68%

High Failure Rate Associated With 180?? Selective Laser Trabeculoplasty

Song

Lee

Epstein

et al. 2005

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 68%

High Failure Rate Associated With 180?? Selective Laser Trabeculoplasty

Song

Lee

Epstein

et al. 2005

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…In 15 studies the medication studied was not an antiglaucoma medication (Ascaso 1992; Bucci 1987; Champagne 2015; De Keyser 2017 (identified as a journal article and a trial record); Diestelhorst 1995; Gelfand 1985; Herbort 1992; Herbort 1993; Jinapriya 2014; Kim 1998; Pappas 1985; Realini 2010; Shin 1996; Weinreb 1983; West 1992). Four studies included participants who also received laser peripheral iridotomies and neodymium:YAG laser capsulotomy without separating the results based on the type of laser performed (Chen 2001; Chen 2005; Patel 1998; Stingu 2001).…”

Section: Resultsmentioning

confidence: 99%

Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

Zhang¹,

Weizer

Musch

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Glaucoma is the international leading cause of irreversible blindness. Intraocular pressure (IOP) is the only currently known modifiable risk factor; it can be reduced by medications, incisional surgery, or laser trabeculoplasty (LTP). LTP reduces IOP by 25% to 30% from baseline, but early acute IOP elevation after LTP is a common adverse effect. Most of these IOP elevations are transient, but temporarily elevated IOP may cause further optic nerve damage, worsening of glaucoma requiring additional therapy, and permanent vision loss. Antihypertensive prophylaxis with medications such as acetazolamide, apraclonidine, brimonidine, dipivefrin, pilocarpine, and timolol have been recommended to blunt and treat the postoperative IOP spike and associated pain and discomfort. Conversely, other researchers have observed that early postoperative IOP rise happens regardless of whether people receive perioperative glaucoma medications. It is unclear whether perioperative administration of antiglaucoma medications may be helpful in preventing or reducing the occurrence of postoperative IOP elevation. Objectives To assess the effectiveness of medications administered perioperatively to prevent temporarily increased intraocular pressure (IOP) after laser trabeculoplasty (LTP) in people with open-angle glaucoma (OAG). Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 11), MEDLINE Ovid (1946 to 18 November 2016), Embase.com (1947 to 18 November 2016), PubMed (1948 to 18 November 2016), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 to 18 November 2016), the metaRegister of Controlled Trials (mRCT) ( www.controlled-trials.com); last searched 17 September 2013, ClinicalTrials.gov (www.clinicaltrials.gov); searched 18 November 2016 and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 18 November 2016. We did not use any date or language restrictions. Selection criteria We included randomized controlled trials (RCTs) in which participants with OAG received LTP. We included trials which compared any antiglaucoma medication with no medication, one type of antiglaucoma medication compared with another type of antiglaucoma medication, or different timings of medication. Data collection and analysis Two review authors independently screened records retrieved by the database searches, assessed the risk of bias, and abstracted data. We graded the certainty of the evidence using GRADE. Main results We included 22 trials that analyzed 2112 participants and identified no ongoing trials. We performed several comparisons of outcomes: one comparison of any antiglaucoma medication versus no medication or placebo, three comparisons of one antiglaucoma medication versus a different antiglaucoma mediation, and one comparison of antiglaucoma medication given before LTP to the same antiglaucoma medication given after LTP. Only one of the included trials used selective laser trabeculopl...

show abstract

“…It is well-known that ALT frequently causes both initial increase and a subsequent decrease of IOP in the early post-laser hours and days (Ruderman et al 1983, Weinreb et al 1984, Pappas et al 1985, The Glaucoma Laser Trial Research Group 1989, Mittra et al 1995, The Brimonidine-ALT Study Group 1995, Shin et al 1996. Since human ALT is followed by an acute increase of the protein concentration in the aqueous humour (Weinreb et al 1984, Shin et al 1996, it is probable that the concentration of endothelins, including ET-1, also becomes elevated in the anterior chamber after laser treatment.…”

Section: Discussionmentioning

confidence: 99%

Increase of endothelin‐1 concentration in aqueous humour induced by argon laser trabeculoplasty in the rabbit. A preliminary study

Holló

Lakatos

1998

Acta Ophthalmologica Scandinavica

View full text Add to dashboard Cite

ABSTRACT.Purpose: To investigate the impact of argon laser trabeculoplasty (ALT) on endothelin-1 (ET-1) concentration of aqueous humour and intraocular pressure (IOP) in the rabbit. Methods: Standard ALT was performed on one eye of 19 pigmented rabbits. A modified treatment in which the laser light was focused on the inner limbal surface (argon laser scleroplasty, ALS) was also performed on one eye of a further 15 rabbits. IOP was measured with a Tono-Pen-2 tonometer before treatment, under general anaesthesia. Post-laser IOP measurements followed by aqueous humour aspiration were performed under general anaesthesia 4, 24 and 120 hours after treatment. IOP readings were considered relative values, since the tonometer was calibrated to the human eye and not to the rabbit eyeball. Different groups of animals were used for the tests after each time period. The groups of 4 hours time consisted of 9 animals which had undergone ALT and 5 which had undergone ALS. All the other groups consisted of 5 animals each. Results: In the ALT group IOP decreased following treatment, and the IOP change (a relative change) showed a significant difference between the treated and the control eyes at all three follow-up times (paired t-test, p∞0.05), and a significant interaction was found between treatment and follow-up time (ANOVA, p∞0.05). Concentration of ET-1 in the aqueous humour of the treated eyes increased by about an order of magnitude 4 hours after ALT, compared to the contralateral control eyes (103.66∫41.59 pg /ml versus 8.75∫2.95 pg/ml, Wilcoxon matched pairs test, p∞0.01). ET-1 concentration 24 and 120 hours after ALT, however, did not differ significantly from the corresponding contralateral control values. In the ALS group neither IOP change nor aqueous humour ET-1 concentration differed in a statistically significant manner between the treated and control eyes. Conclusions:The results suggest that ALT is followed by an immediate and short-term increase of aqueous humour ET-1 concentration in the rabbit, probably due to leakage from the uveal tissue.

show abstract

Topical Indomethacin Therapy Before Argon Laser Trabeculoplasty

Cited by 30 publications

References 16 publications

High Failure Rate Associated With 180?? Selective Laser Trabeculoplasty

High Failure Rate Associated With 180?? Selective Laser Trabeculoplasty

Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty

Increase of endothelin‐1 concentration in aqueous humour induced by argon laser trabeculoplasty in the rabbit. A preliminary study

Contact Info

Product

Resources

About